Ethylene Glycol

Ethylene Glycol

SCHEMBL2829965

COc1c(F)c(F)cc(C(=O)O)c1F.COc1c(F)c(F)cc(C(=O)O)c1F.OCCO

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
APEX1 P27695 3/20 0.36
TPMT P51580 1/20 0.36
PKM P14618 1/20 0.36
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
KEAP1 Q14145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,4-Butanediol SCHEMBL2831393 0.94 HSD17B10 (0.38) HSD17B10MEN1KMT2AMAPTLMNA
1,3-Propanediol SCHEMBL2834709 0.94 HSD17B10 (0.38) HSD17B10MEN1KMT2AMAPTLMNA
SCHEMBL607945 0.93 HSD17B10 (0.44) HSD17B10MEN1KMT2AMAPTLMNA
Ethylene Glycol SCHEMBL2166684 0.93 FABP4 (0.38) HSD17B10MEN1KMT2AAPEX1SMN1; SMN2
SCHEMBL27927680 0.91 HSD17B10 (0.43) HSD17B10MEN1KMT2AMAPTLMNA
Methylene Chloride SCHEMBL28420789 0.90 HSD17B10 (0.40) HSD17B10MEN1KMT2AMAPTLMNA
SCHEMBL2838557 0.89 HSD17B10 (0.37) HSD17B10MEN1KMT2AMAPTLMNA
Ethylene Glycol SCHEMBL2166957 0.88 FABP4 (0.33) HSD17B10MEN1KMT2AMAPTLMNA
Propylene Glycol SCHEMBL2834441 0.88 HSD17B10 (0.36) HSD17B10MEN1KMT2AMAPTLMNA
1,4-Butanediol SCHEMBL2166784 0.87 FABP4 (0.36) HSD17B10MEN1KMT2AMAPK1APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 HSD17B10 254/4885MEN1 2371/4885KMT2A 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.